Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
NCT07011576Phase 2Recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by SCRI Development Innovations. Started Sep 2025; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07011576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011576.